Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.62 |
| ▸ | CASP1 | P29466 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.43 |
| ▸ | CASP7 | P55210 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GNRHR | P30968 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465272 | 0.77 | AR (1.00) | ARCASP1HSD17B10CASP7KDM4E | |
| SCHEMBL6468892 | 0.74 | AR (0.77) | ARHSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL6465363 | 0.70 | AR (0.76) | ARCASP1HSD17B10CASP7KDM4E | |
| SCHEMBL6464186 | 0.68 | AR (0.81) | ARHSD17B10ALDH1A1 | |
| SCHEMBL6464840 | 0.68 | AR (0.78) | ARPTGDR2 | |
| SCHEMBL30109090 | 0.68 | SLC22A12 (0.51) | KDM4EGLAGAASLC22A12 | |
| SCHEMBL6466418 | 0.67 | AR (0.80) | ARCASP1HSD17B10CASP7KDM4E | |
| SCHEMBL6464828 | 0.67 | AR (0.77) | ARCASP1HSD17B10CASP7KDM4E | |
| SCHEMBL4098033 | 0.67 | AR (0.49) | ARCASP1HSD17B10CASP7APP | |
| SCHEMBL28265806 | 0.67 | GUSB (0.52) | KDM4EALDH1A1PTGDR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | AR 6/4885CASP1 4628/4885HSD17B10 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.